Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease.
West RL; Zelinkova Z; Wolbink GJ; Kuipers EJ; Stokkers PC; van der Woude CJ; Alimentary Pharmacology & Therapeutics, 2008, vol. 28, issue 9, p 1122, ISSN 13652036. ISBN 13652036.

Full Text Resources Located for this Citation

View article on EBSCOhost(Login required)
View article via CrossRef